These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27816107)

  • 41. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A point mutation in the neu-1 locus causes the neuraminidase defect in the SM/J mouse.
    Rottier RJ; Bonten E; d'Azzo A
    Hum Mol Genet; 1998 Feb; 7(2):313-21. PubMed ID: 9425240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.
    Beck M
    Hum Genet; 2007 Mar; 121(1):1-22. PubMed ID: 17089160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The 1.9 A structure of alpha-N-acetylgalactosaminidase: molecular basis of glycosidase deficiency diseases.
    Garman SC; Hannick L; Zhu A; Garboczi DN
    Structure; 2002 Mar; 10(3):425-34. PubMed ID: 12005440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are there useful biochemical markers of disease activity in lysosomal storage diseases?
    Winchester B
    J Inherit Metab Dis; 2001; 24 Suppl 2():52-6; discussion 45-6. PubMed ID: 11758679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Metabolic pathway of the degradation of macromolecules by lysosomal enzymes].
    Arai K; Ohkuma S
    Nihon Rinsho; 1995 Dec; 53(12):2904-10. PubMed ID: 8577033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological chaperone therapy for lysosomal storage disorders - leveraging aspects of the folding pathway to maximize activity of misfolded mutant proteins.
    Fan JQ
    FEBS J; 2007 Oct; 274(19):4943. PubMed ID: 17894778
    [No Abstract]   [Full Text] [Related]  

  • 49. Characterization of
    Sellin J; Schulze H; Paradis M; Gosejacob D; Papan C; Shevchenko A; Psathaki OE; Paululat A; Thielisch M; Sandhoff K; Hoch M
    Dis Model Mech; 2017 Jun; 10(6):737-750. PubMed ID: 28389479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chemical chaperone therapy for lysosomal storage diseases].
    Higaki K; Nanba E
    Seikagaku; 2015 Oct; 87(5):597-600. PubMed ID: 26638628
    [No Abstract]   [Full Text] [Related]  

  • 51. Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease.
    Seemann S; Ernst M; Cimmaruta C; Struckmann S; Cozma C; Koczan D; Knospe AM; Haake LR; Citro V; Bräuer AU; Andreotti G; Cubellis MV; Fuellen G; Hermann A; Giese AK; Rolfs A; Lukas J
    Biochem J; 2020 Jan; 477(2):359-380. PubMed ID: 31899485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunocytochemistry of lysosomal hydrolases and their precursor forms in normal and mutant human cells.
    Van Dongen JM; Barneveld RA; Geuze HJ; Galjaard H
    Histochem J; 1984 Sep; 16(9):941-54. PubMed ID: 6480399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pathology of lysosomal storage diseases.
    Agamanolis DP
    Pathol Annu; 1995; 30 ( Pt 1)():247-85. PubMed ID: 7731742
    [No Abstract]   [Full Text] [Related]  

  • 54. Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.
    Yu Z; Sawkar AR; Whalen LJ; Wong CH; Kelly JW
    J Med Chem; 2007 Jan; 50(1):94-100. PubMed ID: 17201413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.
    Mu TW; Fowler DM; Kelly JW
    PLoS Biol; 2008 Feb; 6(2):e26. PubMed ID: 18254660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lysosome: The metabolic signaling hub.
    Lamming DW; Bar-Peled L
    Traffic; 2019 Jan; 20(1):27-38. PubMed ID: 30306667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human β-glucuronidase: structure, function, and application in enzyme replacement therapy.
    Naz H; Islam A; Waheed A; Sly WS; Ahmad F; Hassan I
    Rejuvenation Res; 2013 Oct; 16(5):352-63. PubMed ID: 23777470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology.
    Pshezhetsky AV; Ashmarina M
    Prog Nucleic Acid Res Mol Biol; 2001; 69():81-114. PubMed ID: 11550799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary biochemical and morphological consequences in lysosomal storage diseases.
    Alroy J; Garganta C; Wiederschain G
    Biochemistry (Mosc); 2014 Jul; 79(7):619-36. PubMed ID: 25108325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent progress of lysosomal diseases.
    Durand P
    Enzyme; 1987; 38(1-4):256-61. PubMed ID: 3326733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.